---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041275"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:48:49.448568+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Reneo Q2 net loss $19.5M; STRIDE topline results expected Q4 2023

## Summary
- Net loss $19.5M ($0.65/share) vs $12.3M ($0.50) in Q2 2022.
- Cash and investments $142.7M as of June 30; raised $68.3M gross in May offering.
- Topline data from pivotal mavodelpar STRIDE study in PMM due in Q4 2023.
- Over 130 patients enrolled in STRIDE AHEAD OLE study; criteria expanded to nDNA defects.
- R&D expenses $14.4M (up from $8.1M) driven by clinical and manufacturing costs for mavodelpar.

## SEC filing metadata
- accession: 0000950170-23-041275
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/0000950170-23-041275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/rphm-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041275
- JSON: https://secwatch.observer/filing/0000950170-23-041275.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041275.txt

## Key facts
- Earnings Releases
  OnKure Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $19.5 million, or $0.65 per share, EPS $0.65 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: net loss of $19.5 million, or $0.65 per share
  - EPS: $0.65 per share
  - Result: reported results
  source text: On August 10, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) issued a press release reporting the Company’s financial results for the second quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/0000950170-23-041275-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.